Conjunctivitis in dupilumab clinical trials.

Br J Dermatol · 2019 · PMC6850316 · PMID 30851191

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Dupilumab exposure and conjunctivitis Pooled data from baseline to week 16 in SOLO 1 and 2 and CHRONOS showed a trend suggesting that conjunctivitis incidence may decrease with higher trough concentrations of dupilumab (Table S4 ; see Supporting Information).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.